Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women
| Autor: | Vivian W. Wang, Tony K.H. Chung, Keith W.K. Lo, David I. Smith, So Fan Yim, Yick Fu Wong, Raymond R.Y. Wong, Ida P.C. Lee, Mei Yun Yu, Tak Hong Cheung, Rossa W.K. Chiu, Michael J. Worley, Kitty K.M. Lau, Kevin M. Elias, Ross S. Berkowitz, Stephen Fiascone |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Pathology Class I Phosphatidylinositol 3-Kinases DNA Mutational Analysis Uterine Cervical Neoplasms Adenocarcinoma Polymerase Chain Reaction Disease-Free Survival law.invention 03 medical and health sciences Phosphatidylinositol 3-Kinases 0302 clinical medicine Asian People law Internal medicine Biopsy Carcinoma Biomarkers Tumor Medicine Humans Digital polymerase chain reaction Liquid biopsy neoplasms Polymerase chain reaction Cervical cancer medicine.diagnostic_test business.industry Obstetrics and Gynecology Cancer DNA Neoplasm Middle Aged medicine.disease Tumor Burden 030104 developmental biology 030220 oncology & carcinogenesis Carcinoma Squamous Cell Biomarker (medicine) Feasibility Studies Hong Kong Female business |
| Zdroj: | Gynecologic oncology. 146(2) |
| ISSN: | 1095-6859 |
| Popis: | Introduction Cervical cancer is the fourth most common female cancer worldwide. The prognosis for women with advanced-stage or recurrent cervical cancer remains poor and response to treatment is variable. Standardized management protocols leave little room for individualization. We report on a novel blood-based liquid biopsy for specific PIK3CA mutations as a clinically useful biomarker in patients with invasive cervical cancer. Methods One hundred seventeen Hong Kong Chinese women with primary invasive cervical cancer and their pre-treatment plasma samples were investigated. Two PIK3CA mutations, p.E542K and p.E545K were measured in cell free DNA (cfDNA) extracted from plasma using droplet digital PCR. This liquid biopsy of PIK3CA in cervical cancer was correlated to clinico-pathological features to verify the potential of PIK3CA as a clinically useful molecular biomarker for predicting disease prognosis and monitoring for progression. Results PIK3CA mutations, either p.E542K or p.E545K, were detected in plasma cfDNA from 22.2% of the patients. PIK3CA mutation status was significantly correlated to median tumor size ( p PIK3CA mutations detected in the plasma were significantly associated with decreased disease-free survival and overall survival ( p Conclusions As a liquid molecular biopsy, analysis of circulating PIK3CA mutations shows promise as a way to refine risk stratification of individual patients with cervical cancer, and provides a platform for further research to offer individualized therapy with the purpose of improving outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect